The Experts below are selected from a list of 1086 Experts worldwide ranked by ideXlab platform

Ghulam Nabi - One of the best experts on this subject based on the ideXlab platform.

  • selective sampling using confocal raman spectroscopy provides enhanced specificity for urinary Bladder Cancer Diagnosis
    Analytical and Bioanalytical Chemistry, 2012
    Co-Authors: Ishan Barman, Narahara Chari Dingari, Gajendra P Singh, Rajesh Kumar, Stephen Lang, Ghulam Nabi
    Abstract:

    In recent years, Raman spectroscopy has shown substantive promise in diagnosing Bladder Cancer, especially due to its exquisite molecular specificity. The ability to reduce false detection rates in comparison to existing diagnostic tools such as photodynamic Diagnosis makes Raman spectroscopy particularly attractive as a complementary diagnostic tool for real-time guidance of transurethral resection of Bladder tumor (TURBT). Nevertheless, the state-of-the-art high-volume Raman spectroscopic probes have not reached the expected levels of specificity thereby impeding their clinical translation. To address this issue, we propose the use of a confocal Raman probe for Bladder Cancer Diagnosis that can boost the specificity of the diagnostic algorithm based on its suppression of the out-of-focus non-analyte-specific signals emanating from the neighboring normal tissue. In this article, we engineer and apply such a probe, having depth of field of approximately 280 μm, for Raman spectral acquisition from ex vivo normal and Cancerous TURBT samples. Using this clinical dataset, a diagnostic algorithm based on principal component analysis and logistic regression is developed. We demonstrate that this approach results in comparable sensitivity but significantly higher specificity in relation to high-volume Raman spectral data. The application of only two principal components is sufficient for the discrimination of the samples underlining the robustness of the algorithm. Further, no discordance between replicate spectra is observed emphasizing the reproducible nature of the current diagnostic assessment. The high levels of sensitivity and specificity achieved in this proof-of-concept study opens substantive avenues for application of a confocal Raman probe during endoscopic procedures related to Diagnosis and treatment of Bladder Cancer.

  • Potential of urinary biomarkers in early Bladder Cancer Diagnosis
    Expert Review of Anticancer Therapy, 2007
    Co-Authors: Ghulam Nabi
    Abstract:

    Carcinoma of urinary Bladder ranks among the top ten most common Cancers worldwide. Approximately 80% of the disease is superficial (limited to mucosa and lamina propria) at the time of presentation. However, the majority of these tumors recur and 15–20% progress into muscle-invasive disease. Cystoscopic surveillance of the urinary Bladder remains the standard of care to identify these recurrences on follow-up. Not only is this an invasive procedure, but the sensitivity of cystoscopy can be as low as 70%, so there can be up to 30% of tumors that are missed. Urinary cytology, with recognized limitations, has been used as an adjunct to this procedure, pending discovery of alternate urinary biomarkers. In the past decade there has been tremendous advancement in producing urinary biomarkers for urinary Bladder Cancer research, reflecting advancements in genomics and proteomics. An ideal biomarker should be able to replace cystoscopic examination and be cost effective. Unfortunately, most of the identified pro...

Maureen Twiddy - One of the best experts on this subject based on the ideXlab platform.

  • The patients’ experience of a Bladder Cancer Diagnosis: a systematic review of the qualitative evidence
    Journal of Cancer Survivorship, 2017
    Co-Authors: Amanda J. Edmondson, Jacqueline C. Birtwistle, James W.f. Catto, Maureen Twiddy
    Abstract:

    Purpose Bladder Cancer (BC) is a common disease with disparate treatment options and variable outcomes. Despite the disease’s high prevalence, little is known of the lived experience of affected patients. National patient experience surveys suggest that those with BC have poorer experiences than those with other common Cancers. The aim of this review is to identify first-hand accounts of the lived experiences of Diagnosis through to survivorship. Method This is a systematic review of the qualitative evidence reporting first-hand accounts of the experiences of being diagnosed with, treated for and surviving Bladder Cancer. A thematic analysis and ‘best-fit’ framework synthesis was undertaken to classify these experiences. Results The inconsistent nature of symptoms contributes to delays in Diagnosis. Post-Diagnosis, many patients are not actively engaged in the treatment decision-making process and rely on their doctor’s expertise. This can result in patients not adequately exploring the consequences of these decisions. Learning how to cope with a ‘post-surgery body’, changing sexuality and incontinence are distressing. Much less is known about the quality of life of patients receiving conservative treatments such as Bacillus Calmette-Guerin (BCG). Conclusions The review contributes to a greater understanding of the lived experience of Bladder Cancer. Findings reflect a paucity of relevant literature and a need to develop more sensitive patient-reported outcome measures (PROMs) and incorporate patient-reported outcomes in BC care pathways. Implications for Cancer survivors Collective knowledge of the patients’ self-reported experience of the Cancer care pathway will facilitate understanding of the outcomes following treatment.

  • the patients experience of a Bladder Cancer Diagnosis a systematic review of the qualitative evidence
    Journal of Cancer Survivorship, 2017
    Co-Authors: Amanda J. Edmondson, Jacqueline C. Birtwistle, James W.f. Catto, Maureen Twiddy
    Abstract:

    Purpose Bladder Cancer (BC) is a common disease with disparate treatment options and variable outcomes. Despite the disease’s high prevalence, little is known of the lived experience of affected patients. National patient experience surveys suggest that those with BC have poorer experiences than those with other common Cancers. The aim of this review is to identify first-hand accounts of the lived experiences of Diagnosis through to survivorship.

Zhenguo Wang - One of the best experts on this subject based on the ideXlab platform.

  • Endoscopic optical coherence tomography for Bladder Cancer Diagnosis
    2007
    Co-Authors: Zhenguo Wang
    Abstract:

    Stony Brook University Libraries. SBU Graduate School in Biomedical Engineering. Lawrence Martin (Dean of Graduate School), Yingtian Pan, Ph.D. Dissertation Advisor Associate Professor, Biomedical Engineering Department, Ki H. Chon, Ph.D. Chairperson of Defense Associate Professor, Biomedical Engineering Department, Emilia Entcheva , Ph.D. Committee Member Associate Professor, Biomedical Engineering Department, Christopher S. D. Lee, M.D. Committee Member Assistant Professor, Department of Urology, Stony Brook University Hospital.

  • Bladder Cancer Diagnosis with fluorescence guided spectral domain optical coherence tomography in a rat model
    2007 IEEE 33rd Annual Northeast Bioengineering Conference, 2007
    Co-Authors: Zhenguo Wang, M. Hasan
    Abstract:

    A fluorescence-image-guided spectral domain OCT (FG-SDOCT) system is described. With the recent development of spectral domain OCT, the new system is able to visualize morphological details of urinary Bladder with high image fidelity (e.g., 10um/12um axial/lateral resolutions, >110dB dynamic range) at 4~8-fold improved frame rate. Ex vivo study based on an AY-27 rat Cancer model was performed to evaluate its ability to enhance the sensitivity and specificity. Total 82 specimens were examined by hyperisin-induced fluorescence imaging, OCT and histological microscopy sequentially. The preliminary results demonstrate the sensitivity and specificity of FG-SDOCT is 100% and 90% respectively, compared to 85% and 49% for fluorescence imaging. This significant improvement indicates that FG-OCT is a very promising technique for effective early Bladder Cancer Diagnosis in combination of endoscopic OCT.

  • INTERPIXEL-SHIFTED ENDOSCOPIC OPTICAL COHERENCE TOMOGRAPHY FOR IN VIVO Bladder Cancer Diagnosis
    International Journal of Image and Graphics, 2007
    Co-Authors: Zhenguo Wang, Wayne C. Waltzer, Zhijia Yuan
    Abstract:

    An interpixel-shifted spectral imaging technique is applied to MEMS-based spectral-domain endoscopic optical coherence tomography (SDEOCT) to enhance signal-to-noise ratio and effective imaging depth for in vivo imaging Diagnosis of biological tissue. To validate the enhancements of pixel-shifted SDEOCT, experimental comparisons are presented to image animal and human Bladder architectures in vivo and to diagnose human transitional cell Cancers. Preliminary study shows that interpixel shifted SDEOCT not only increases the depth of field of SDOCT but also eliminates excessive artifacts induced by spectral aliasing effect, thus improving image contrast in areas with large depths (e.g. over 1.5 mm). These results suggest that endoscopic OCT equipped with interpixel-shifted spectral camera has the potential to enhance the Diagnosis of biological tissue in in vivo settings that require a larger field of view in the axial direction, such as papillary Bladder tumors with deep surface irregularities (e.g. asperities or invaginations).

  • Endoscopic Fourier Domain Optical Coherence Tomography for Bladder Cancer Diagnosis
    Biosilico, 2006
    Co-Authors: Zhenguo Wang, Zhijia Yuan, Hongyu Wang, Zilu Wu
    Abstract:

    We report a newly developed endoscopic OCT system which incorporates Fourier-domain optical coherence tomography and MEMS mirror for endoscopic laser scanning to improve the frame rate and the dynamic range of the imaging system.

  • Bladder Cancer Diagnosis with fluorescence-image-guided optical coherence tomography
    Biomedical optics, 2006
    Co-Authors: Zhenguo Wang, D. B. Durand, Howard L. Adler
    Abstract:

    A fluorescence-image-guided OCT (FIG-OCT) system is described, and its ability to enhance the sensitivity and specificity is examined in an animal Bladder Cancer model. Total 97 specimens were examined by fluorescence imaging, OCT and histological microscopy. The sensitivity and specificity of FIG-OCT is 100% and 93% respectively, compared to 79% and 53% for fluorescence imaging, while the OCT examination time has been dramatically decreased by 3~4 times. In combination of endoscopic OCT, FIG-OCT is a promising technique for effective early Bladder Cancer Diagnosis.

Amanda J. Edmondson - One of the best experts on this subject based on the ideXlab platform.

  • The patients’ experience of a Bladder Cancer Diagnosis: a systematic review of the qualitative evidence
    Journal of Cancer Survivorship, 2017
    Co-Authors: Amanda J. Edmondson, Jacqueline C. Birtwistle, James W.f. Catto, Maureen Twiddy
    Abstract:

    Purpose Bladder Cancer (BC) is a common disease with disparate treatment options and variable outcomes. Despite the disease’s high prevalence, little is known of the lived experience of affected patients. National patient experience surveys suggest that those with BC have poorer experiences than those with other common Cancers. The aim of this review is to identify first-hand accounts of the lived experiences of Diagnosis through to survivorship. Method This is a systematic review of the qualitative evidence reporting first-hand accounts of the experiences of being diagnosed with, treated for and surviving Bladder Cancer. A thematic analysis and ‘best-fit’ framework synthesis was undertaken to classify these experiences. Results The inconsistent nature of symptoms contributes to delays in Diagnosis. Post-Diagnosis, many patients are not actively engaged in the treatment decision-making process and rely on their doctor’s expertise. This can result in patients not adequately exploring the consequences of these decisions. Learning how to cope with a ‘post-surgery body’, changing sexuality and incontinence are distressing. Much less is known about the quality of life of patients receiving conservative treatments such as Bacillus Calmette-Guerin (BCG). Conclusions The review contributes to a greater understanding of the lived experience of Bladder Cancer. Findings reflect a paucity of relevant literature and a need to develop more sensitive patient-reported outcome measures (PROMs) and incorporate patient-reported outcomes in BC care pathways. Implications for Cancer survivors Collective knowledge of the patients’ self-reported experience of the Cancer care pathway will facilitate understanding of the outcomes following treatment.

  • the patients experience of a Bladder Cancer Diagnosis a systematic review of the qualitative evidence
    Journal of Cancer Survivorship, 2017
    Co-Authors: Amanda J. Edmondson, Jacqueline C. Birtwistle, James W.f. Catto, Maureen Twiddy
    Abstract:

    Purpose Bladder Cancer (BC) is a common disease with disparate treatment options and variable outcomes. Despite the disease’s high prevalence, little is known of the lived experience of affected patients. National patient experience surveys suggest that those with BC have poorer experiences than those with other common Cancers. The aim of this review is to identify first-hand accounts of the lived experiences of Diagnosis through to survivorship.

Dino Amadori - One of the best experts on this subject based on the ideXlab platform.

  • urine cell free dna integrity as a marker for early Bladder Cancer Diagnosis preliminary data
    Urologic Oncology-seminars and Original Investigations, 2013
    Co-Authors: Valentina Casadio, Daniele Calistri, Michela Tebaldi, Sara Bravaccini, Roberta Gunelli, Giuseppe Martorana, Alessandro Bertaccini, Luigi Serra, Emanuela Scarpi, Dino Amadori
    Abstract:

    Abstract Objectives Urine cell-free (UCF) DNA has recently been proposed as a potential marker for early Bladder Cancer Diagnosis. It is known that normal apoptotic cells produce highly fragmented DNA while Cancer cells release longer DNA. Therefore, we verified the potential role of UCF DNA integrity in early Bladder Cancer Diagnosis. Materials and methods UCF DNA was isolated from 51 Bladder Cancer patients, 46 symptomatic patients, and 32 healthy volunteers. To verify UCF DNA integrity, sequences longer than 250 bp, c-Myc , BCAS1 , and HER2 , were quantified by real time PCR. Results At the best cutoff value of 0.1 ng/μl, UCF DNA integrity analysis showed a sensitivity of 0.73 (95% CI 0.61–0.85), and a specificity of 0.84 (95% CI 0.71–0.97) in healthy individuals and 0.83 (95% CI 0.72–0.94) in symptomatic patients. Receiver operating characteristic (ROC) curve analysis revealed an area under the curve of 0.834 (95% CI 0.739–0.930) for healthy individuals and 0.796 (95% CI 0.707–0.885) for symptomatic patients. Conclusions These preliminary data suggest that UCF DNA integrity is a potentially good marker for early noninvasive Diagnosis of Bladder Cancer. Its diagnostic performance does not seem to vary significantly, even in an “at risk” population of symptomatic individuals.

  • Urinary biomarkers of non-muscle-invasive Bladder Cancer: Current status and future potential
    Expert Review of Anticancer Therapy, 2012
    Co-Authors: Daniele Calistri, Valentina Casadio, Sara Bravaccini, Wainer Zoli, Dino Amadori
    Abstract:

    Bladder Cancer Diagnosis and patient surveillance present a wide range of diagnostic methods but essentially only instrumental approaches are available in the clinical setting. Although numerous new noninvasive biomarkers have been proposed in the last 10 years, few are US FDA-approved for clinical purposes, and none are widely used in routine clinical practice. In this review, we summarize the tests developed for early Diagnosis and patient surveillance and verify whether, for any, there is some level of evidence to suggest a real usefulness in a clinical setting.

  • Abstract 2740: Increased accuracy of TRAP-FISH combination in Bladder Cancer Diagnosis in symptomatic patients
    Cancer Research, 2010
    Co-Authors: Sara Bravaccini, Valentina Casadio, Roberta Gunelli, Dino Amadori, Oriana Nanni, Chiara Arienti, Emanuele Sacanna, Wainer Zoli, Rosella Silvestrini, Daniele Calistri
    Abstract:

    Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Introduction: Previous case-control studies have shown the importance of urine telomerase activity determined by the telomerase repeat amplification protocol (TRAP) assay to detect early Bladder Cancer. However, its validation is needed in large and consecutive series of symptomatic patients before it can be considered for routine clinical use. The aim of the present study was to verify whether a multiple approach based on first-level TRAP assay analysis and successive evaluation with UroVysion test, limited to patients with TRAP-positive urine samples, could unmask false-positive results and improve diagnostic specificity. Patients and methods: Three hundred individuals with urinary tract symptomatology (50 females, 250 males), but without prior history of Bladder malignancy were consecutively enrolled between January 2007 and June 2008. All urine samples were processed for cytological examination and also for telomerase activity determination using a quantitative TRAP assay. FISH analysis was carried out only in TRAP-positive samples. Results: At a cut-off of 50 arbitrary enzymatic units (AEUs), shown in previous case control-studies as the most accurate diagnostic discriminant, the positive predictive value (PPV) and negative predictive value (NPV) using TRAP assay were 48% and 86%, respectively, with an overall accuracy of 71%. With the two-step TRAP-FISH approach, PPV increased to 75% and overall accuracy to 83%. Conclusion: Our results indicate that TRAP assay by itself could make a valid contribution to early Bladder Cancer Diagnosis in high-risk patients with urinary tract symptomatology, and that its combination with FISH could improve specificity by unmasking false-positive TRAP results. *Contributed equally to this work Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2740.